Ann: Prescient to Present at AVID 2022 Meeting, page-23

Sorry mste. missed this post.

The data from this presentation has been released before. Check out the original announcement from Oct last year, and the investor presentation from March this year.

Some awesome data presented, that I hadnt really taken on board until checking this recently with Shellbell.

This data shows how spycatcher 3 is multiples of capabilities more effective than the original spycatcher concept. Which I think we all knew. But reading how it treats mutating cancer types by multi arming/re-arming is a concept i hadnt fully understood. This mutating of cancer cells is a major road block in some cancer treatments. And spycatcher is a very effective fix.

I had always thought that 3rd gen CarT had progressed beyond the help that Omnicar could provide. I was thinking more in terms of safety. But now I see I wss wrong.

The concept is that drugs/treatments are available that can easy kill cancer cells of the right type, but stop being effective if that same cancer mutates to prevent this killer drug/treatment identifying and binding to and killing the mutsted cell. Spycatcher 3 can be aimed with muliple binders. or if treatment starts to become less effective. it can be rearmed with new binders. No new Tcells need to be manufactured and administered. And the mutated cells can now be targeted. This truely becomrs personalised medicine. A good description of how this worked against GBM cells is given. Looks like HER2+ is being investigated first.